Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 1Phase 1/2 1

Status

Active not recruiting 4Recruiting 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 6

Conditions

Carcinoma, Hepatocellular 6Leukemia, Myeloid, Acute 4Neuroblastoma 2Neoplasm Metastasis 2Tongue Neoplasms 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Rhabdomyosarcoma 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasms 1Myelodysplastic Syndromes 1Melanoma 1Hepatoblastoma 1Gastrointestinal Stromal Tumors 1Fibrolamellar hepatocellular carcinoma 1

Interventions

Bevacizumab 36atezolizumab 25durvalumab 22Nivolumab 21lenvatinib 20tremelimumab 15Specimen Handling 15Magnetic Resonance Spectroscopy 12sintilimab 11pembrolizumab 11Ipilimumab 10tislelizumab 7X-Rays 7Radiosurgery 7Immunoglobulin G 7regorafenib 6Sorafenib 6Disulfides 6Cyclophosphamide 6Radiotherapy 5cabozantinib 4Radiation 4Oxaliplatin 4Immunotherapy 4Fluorouracil 4Ethiodized Oil 4Blood Specimen Collection 4Biopsy 4fludarabine 3Photons 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Sorafenib × 90 days × Clear all
NCT05468359 2026-05-19

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

St. Jude Children's Research Hospital

Phase 1/2 Recruiting
64 enrolled
Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma, Hepatocellular, Neoplasms

NCT03017326 2026-05-13

PHITT

University of Birmingham

Phase 3 Active not recruiting
450 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Hepatoblastoma

NCT01840592 2026-05-06

Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
30 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT04039607 2026-04-06

CheckMate 9DW

Bristol-Myers Squibb

Phase 3 Active not recruiting
732 enrolled 1 FDA
Gastrointestinal

Carcinoma, Hepatocellular

NCT03298451 2026-03-20

HIMALAYA

AstraZeneca

Phase 3 Active not recruiting
1,324 enrolled 31 charts 1 FDA
Gastrointestinal

Carcinoma, Hepatocellular

NCT04720716 2026-03-19

A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3 Completed
344 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡